Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMB-100 Intrapleural Perfusion for Pleural Mesothelioma and Effusions
NCT05375825Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jan 2024
- Primary completion
- Jan 2024
- Modality
- Antibody-Drug Conjugates (ADCs), Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of LMB-100 in malignant pleural mesothelioma (MPM) and malignant pleural effusion (MPE) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 21 days. Planned start Jan 2024; status: withdrawn.
02
Drugs
LMB-100
03
Conditions
malignant pleural mesothelioma (MPM)malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT05375825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375825.